News

The new agreement expands the existing collaboration between Epix and Cystic Fibrosis Foundation Therapeutics (CFFT) and increases payments from CFFT by up to $37.7 million. As a result,

The multinational Phase II clinical trial, with an enrollment of 265 patients in three arms, showed nemonoxacin 750mg once daily in an oral dose over a period of

EpiCept has recently analyzed the imaging data from the first eight patients enrolled in the study who had measurable Computed Tomography (CT) perfusion scans. These patients received doses

Mr Waldron’s resignation will be effective as of April, 2008 end, although he will remain a company consultant for at least one year. The company will commence a

The randomized, double-blinded, placebo-controlled, sequential ascending single intravenous dose study of TG-0054 will evaluate the safety, tolerability, pharmacokinetics and the biomarkers, the CD34+ stem cells and the CD133+

The study is designed as a two-part, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of KNS-760704 oral tablets. It will be conducted at approximately 20

The preliminary results of the 28-day, 30-patient, randomized, double-blind, placebo-controlled, crossover study showed that P-552-02 was safe and well tolerated, both locally in the oral cavity and systemically.

The estimated purchase price of $11.1 million is based on performance-based earn-out payments over the next two years. At closing, $8.3 million of the purchase price was paid

Previously, the company’s board of directors has approved a 1-for-17 reverse split of its outstanding common stock. The number of shares of the company’s outstanding common stock will